Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
Open accessThe DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Abstract
Objective: Our objective was to examine the mechanisms via which exenatide attenuates postprandial hyperglycemia in type 2 diabetes mellitus (T2DM). Study Design: Seventeen T2DM patients (44 yr; seven females, 10 males; body mass index = 33.6 kg/m2; glycosylated hemoglobin = 7.9%) received a mixed meal followed for 6 h with double-tracer technique ([1-14C]glucose orally; [3-3H]glucose iv) before and after 2 wk of exenatide. In protocol II (n = 5), but not in protocol I (n = 12), exenatide was given in the morning of the repeat meal. Total and oral glucose appearance rates (RaT and RaO, respectively), endogenous glucose production (EGP), splanchnic glucose uptake (75 g − RaO), and hepatic insulin resistance (basal EGP × fasting plasma insulin) were determined. Results: After 2 wk of exenatide (protocol I), fasting plasma glucose decreased (from 10.2 to 7.6 mm) and mean postmeal plasma glucose decreased (from 13.2 to 11.3 mm) (P < 0.05); fasting and meal-stimulated plasma insulin and glucagon did not change significantly. After exenatide, basal EGP decreased (from 13.9 to 10.8 μmol/kg · min, P < 0.05), and hepatic insulin resistance declined (both P < 0.05). RaO, gastric emptying (acetaminophen area under the curve), and splanchnic glucose uptake did not change. In protocol II (exenatide given before repeat meal), fasting plasma glucose decreased (from 11.1 to 8.9 mm) and mean postmeal plasma glucose decreased (from 14.2 to 10.1 mm) (P < 0.05); fasting and meal-stimulated plasma insulin and glucagon did not change significantly. After exenatide, basal EGP decreased (from 13.4 to 10.7 μmol/kg · min, P = 0.05). RaT and RaO decreased markedly from 0–180 min after meal ingestion, consistent with exenatide's action to delay gastric emptying. Conclusions: Exenatide improves 1) fasting hyperglycemia by reducing basal EGP and 2) postmeal hyperglycemia by reducing the appearance of oral glucose in the systemic circulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have shown an improvement in hepatic glucose and lipid metabolism after GLP-1 injection [167,168] or GLP-1RA treatment [24,102,169,170,171] either in humans and animal studies.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [171]
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“Insulin secretion/insulin resistance (disposition) index was calculated as [ area under the curve (AUC)-insulin secretory rate (ISR)/ AUC-glucose] Matsuda index of insulin sensitivity (21, 22).”
MethodSelf-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 2×
“T2DM subjects have reduced circulating GLP-1 levels (3, 27) and a marked defect in the ability of the liver to dispose of an ingested glucose load (18, 28–30).”
BackgroundGastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Self-citationRole of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611 · cited 1×
“Glucagon-like peptide-1 (GLP-1) receptor agonists represent a new class of antidiabetic agents that have gained widespread use (2, 3).”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Abdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Self-citationThe disposal of an oral glucose load in patients with non-insulin-dependent diabetes
Ferrannini, E., Simonson, D. C., Katz, L. D., Reichard, G., Bevilacqua, S., Barrett, E. J., Olsson, M., & DeFronzo, R. A. (1988) · Metabolism · doi:10.1016/0026-0495(88)90033-9 · Cited by 305 · cited 1×
“RaO was obtained as the difference between total and endogenous glucose appearance rates (18).”
BackgroundSelf-citationDeFronzo, R. A., Ferrannini, E., Hendler, R., Wahren, J., & Felig, P. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.10.5173 · Cited by 296 · cited 1×
“Thus, GLP-1 does not appear to be the long sought after gut factor that explains enhanced SGU after glucose ingestion (29, 30) and deficiency of which accounts for impaired SGU after oral glucose in T2DM (29–31).”
BackgroundSelf-citationD'Alessio, D. A., Kahn, S. E., Leusner, C. R., & Ensinck, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 282
Burcelin, R., Da Costa, A., Drucker, D., & Thorens, B. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1720 · Cited by 250 · cited 1×
“elevated portal vein GLP-1 levels (12, 13).”
Balas, B., Baig, M. R., Watson, C., Dunning, B. E., Ligueros-Saylan, M., Wang, Y., He, Y.-L., Darland, C., Holst, J. J., Deacon, C. F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1882 · Cited by 243
Self-citationBasu, A., Basu, R., Shah, P., Vella, A., Johnson, C. M., Nair, K. S., Jensen, M. D., Schwenk, W. F., & Rizza, R. A. (2000) · Diabetes · doi:10.2337/diabetes.49.2.272 · Cited by 204
ISEC: a program to calculate insulin secretion
Hovorka, R., Soons, P. A., & Young, M. A. (1996) · Computer Methods and Programs in Biomedicine · doi:10.1016/0169-2607(96)01755-5 · Cited by 177
Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021479 · Cited by 173 · cited 1×
“elevated portal vein GLP-1 levels (12, 13).”
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C., Musi, N., DeFronzo, R. A., & Cersosimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 157 · cited 5×
“However, because exenatide delays gastric emptying (8), it is not possible to determine whether the decrease in RaO is explained by increased SGU or delayed gastric emptying and sequestration of the ingested glucose within the stomach.”
BackgroundResultInfluentialSelf-citationGLP-1 does not acutely affect insulin sensitivity in healthy man
Ørskov, L., Holst, J. J., Møller, J., Ørskov, C., Møller, N., Alberti, K. G. M. M., & Schmitz, O. (1996) · Diabetologia · doi:10.1007/bf02658511 · Cited by 123
Vella, A., Shah, P., Basu, R., Basu, A., Holst, J. J., & Rizza, R. A. (2000) · Diabetes · doi:10.2337/diabetes.49.4.611 · Cited by 119
Ferrannini, E., Wahren, J., Felig, P., & DeFronzo, R. A. (1980) · Metabolism · doi:10.1016/0026-0495(80)90094-3 · Cited by 107 · cited 1×
“Thus, GLP-1 does not appear to be the long sought after gut factor that explains enhanced SGU after glucose ingestion (29, 30) and deficiency of which accounts for impaired SGU after oral glucose in T2DM (29–31).”
BackgroundSelf-citationVella, A. V., Shah, P. J., Reed, A. S., Adkins, A., Basu, R., & Rizza, R. A. (2003) · Diabetologia · doi:10.1007/s00125-002-0924-4 · Cited by 96 · cited 1×
“In T2DM, there is both deficiency of GLP-1 (4, 5) and -cell resistance to the stimulatory effect of GLP-1 on in-”
BackgroundBlase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004274432 · Cited by 82 · cited 1×
“The oral glucose load was mixed with 100 Ci 1-(14)C-labeled glucose and 1000 mg acetaminophen elixir (protocol I only) to monitor gastric emptying (17).”
MethodRyan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 81
Ryan, A. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2399 · Cited by 65
Dardevet, D., Moore, M. C., DiCostanzo, C. A., Farmer, B., Neal, D. W., Snead, W., Lautz, M., & Cherrington, A. D. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00121.2005 · Cited by 48 · cited 1×
“(14), net hepatic glucose balance (HGB) (sum of HGP and HGU) was measured, GLP-1 was infused directly into the portal vein, and the increase in net HGB was quite small and not significant in one of the two studies (6).”
BackgroundVella, A., Shah, P., Reed, A. S., Adkins, A., Basu, R., & Rizza, R. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1250-1 · Cited by 36
Exenatide can reduce glucose independent of islet hormones or gastric emptying
Ionut, V., Zheng, D., Stefanovski, D., & Bergman, R. N. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90222.2008 · Cited by 35 · cited 1×
“(16) also suggested that GLP-1 may augment HGU, but no measures of HGU, HGP, ornetHGBweremade toexplain the increase inwhole-body glucose clearance after intraportal GLP-1 infusion.”
BackgroundLACK OF A GASTROINTESTINAL MEDIATOR OF INSULIN ACTION IN MATURITY-ONSET DIABETES
DeFronzo, R. A., Wahren, J., Ferrannini, E., & Felig, P. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91807-x · Cited by 34
Self-citationEdgerton, D. S., Johnson, K. M. S., Neal, D. W., Scott, M., Hobbs, C. H., Zhang, X., Duttaroy, A., & Cherrington, A. D. (2009) · Diabetes · doi:10.2337/db08-0515 · Cited by 33 · cited 1×
“(15), both glucose and GLP-1 were delivered into the portal vein and vildagliptin (dipeptidyl peptidase-4 inhibitor) was given orally.”
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
Triplitt, C., & DeFronzo, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.3.329 · Cited by 25 · cited 1×
“Because the inhibitory effect of exenatide on gastric emptying is related to the prevailing plasma exenatide concentration and is not observed until pharmacological levels of the GLP-1 analog are reached (32), it will be difficult in man to evaluate the effect of exenatide on SGU.”
BackgroundSelf-citationJohnson, K., Edgerton, D. S., Rodewald, T., Scott, M. F., Farmer, B., Neal, D. W., & Cherrington, A. D. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00642.2007 · Cited by 19 · cited 4×
“The appearance of acetaminophen (AUC) in the systemic circulation over the 0–360 min after the meal was similar in the meal test performed before (1481 22 g/ ml) and after (1487 49 g/ml) exenatide (Supplemental J Clin Endocrinol Metab, June 2011, 96(6):1763–1770 jcem.”
BackgroundMethodInfluential
Research works printed but not linked: 1
- Samson, 2009, Exendin 4 down regulates gluconeogenic gene expression and gluconeogenesis in vivo and in isolated hepatocytes in vitro., Diabetes, 58, A3
Cited by
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationPathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
“Increased insulin and inhibited glucagon secretion reduce basal HGP, reducing fasting plasma glucose concentration and enhancing HGP suppression after a meal (98,99).”
BackgroundSelf-citationAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Self-citationBrown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
Kapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
“As noted above, the PPG-lowering effects observed with some GLP-1 receptor agonists (lixisenatide and exenatide, but not liraglutide) appear to be due primarily to slowing of gastric emptying [14,17,29–31].”
Background
Metadata
- Authors
- Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., & DeFronzo, R. A.
- Affiliations
- Division of Diabetes (E.C., A.G., A.C., E.W., A.S., M.F., P.Z., C.T., N.M., R.A.D.), San Antonio, Texas 78229;
- Istituto di Fisiologia Clinica (IT)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, R. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06-01
- Volume
- 96
- Issue
- 6
- Pages
- 1763-1770
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1987319592
- Cited by
- 50
- References
- 36
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 5 · 2013: 12 · 2012: 3
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- green
- puma.isti.cnr.it
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- exenatide, GLP-1 receptor agonists, type 2 diabetes, postprandial hyperglycemia, hepatic insulin resistance, endogenous glucose production, gastric emptying, hepatic glucose production, glucose metabolism, mixed meal tolerance test
- MeSH terms
- Exenatide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucagon, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Venoms, Postprandial Period, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.